Ista tobramycin/prednisolone combo
This article was originally published in Pharmaceutical Approvals Monthly
Ista plans to submit an NDA in the first half of 2006 for a tobramycin/prednisolone combination product for treatment of steroid-responsive inflammatory ocular conditions where risk of bacterial infection exists, the firm says Aug. 4. Ista filed an IND for a Phase III study in the indication during the second quarter...
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.